Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Amgen (AMGN) announced a real-world study showing Repatha reduced fatal or nonfatal heart attack risk by 20% compared with ezetimibe. The non-interventional study included 544,103 adults with atherosclerotic cardiovascular disease, a condition involving plaque buildup in arteries, and prior statin use. Participants started treatment between 2017 and 2024, with follow-up through June 2026 for up to four years.
The analysis included 64,421 Repatha users and 479,682 ezetimibe users. Among 225,048 patients with a baseline LDL cholesterol measurement, four-year cumulative heart attack risk was 5.88% versus 7.76%, respectively. Without that measurement, risks were 5.65% and 7.06%. Researchers used statistical adjustments to balance measured patient characteristics and account for incomplete baseline cholesterol data. The findings were published in The American Journal of Preventive Cardiology.
Merck (NYSE: MRK) reported worldwide sales of $18.1 billion, up 5%, and narrowed its sales outlook while raising the midpoint. Its expected sales range is $66.8 billion–$67.3 billion. KEYTRUDA/KEYTRUDA QLEX sales were $8.6 billion; WINREVAIR sales rose 93% to $694 million.
Other drugmakers also reported growth: Amgen's third-quarter revenue rose 8% to $10.4 billion, Vertex's rose 12% to $3.44 billion, and Incyte's rose 14% to $1.56 billion. Gilead's product sales excluding Veklury increased 16% year over year to $8.2 billion. Gilead, Vertex and Incyte raised their full-year sales or revenue outlooks. Pricing pressures included a 14% decline in Amgen's Enbrel net selling price; Gilead expects a new Medicare price to affect Biktarvy revenue starting January 1, 2028.
The Nasdaq Biotechnology Index rose 2.1% as of 2:31 p.m. ET on November 4, alongside a broader market rally.
Amgen (NASDAQ: AMGN) reported third-quarter 2026 revenue of $10.4 billion, up 8% from the same period last year. GAAP earnings per share rose 19% to $7.08. GAAP operating income increased from $2.5 billion to $3.7 billion, while operating margin, measured against product sales, rose 9.9 percentage points to 37.5%.
Product sales increased 8% to $9,883 million. Repatha sales rose 37% to $1,085 million, while Prolia and XGEVA sales fell 45% and 47%, respectively, following global biosimilar launches. Free cash flow declined to $3.7 billion from $4.2 billion. Cash reached $13.2 billion and debt fell to $54.0 billion at September 30, 2026.
Amgen expects full-year revenue of $38.9 billion–$39.7 billion and GAAP earnings per share of $18.34–$19.28. MariTide Phase 3 cardiovascular and two sleep-apnea studies completed enrollment; other Phase 3 studies remain ongoing or enrolling.
Amgen (AMGN) will report third-quarter 2026 financial results on November 3, 2026, after U.S. financial markets close. A conference call follows at 4:30 p.m. ET, with CEO Robert A. Bradway and other senior managers participating. The public webcast will be available through the Investors section of Amgen's website, with a replay archived for at least 90 days.
Amgen (NASDAQ: AMGN) declared a $2.52 per share dividend for the fourth quarter of 2026, payable on December 11, 2026. The Board of Directors approved the dividend for stockholders of record as of the close of business on November 20, 2026.
Amgen (NASDAQ: AMGN) reported Phase 3 results showing dazodalibep reduced systemic disease activity in adults with Sjögren's disease versus placebo.
At Week 48, disease activity scores fell by 5.6 points with 1,500 mg every four weeks and 5.2 points with 3,000 mg every 12 weeks, versus 3.8 points with placebo. Both comparisons were statistically significant. The every-four-week regimen also significantly improved patient-reported dryness. Adverse events, serious adverse events and adverse events leading to discontinuation occurred at similar rates across groups.
Amgen will present the results at ACR Convergence 2026, alongside UPLIZNA long-term data and KRYSTEXXA and TAVNEOS real-world evidence. The company expects its separate OASIZ 303 study to complete in Q4 2026.
Amgen (NASDAQ: AMGN) appointed David W. Gibbs to its Board of Directors, effective immediately on October 26, 2026. Gibbs will serve on the Audit Committee and the Compensation and Management Development Committee. With his appointment, the board will have 13 directors, 12 of whom are independent.
Gibbs recently retired as president and chief executive officer of Yum! Brands, where he served as CEO from 2020 to 2025. He also serves on the boards of Under Armour and PepsiCo.
Amgen (NASDAQ:AMGN) reported interim Phase 3 results showing IMDELLTRA plus IMFINZI reduced death risk by 58% in first-line lung cancer maintenance.
DeLLphi-305 enrolled patients with extensive-stage small cell lung cancer who had not progressed after initial durvalumab and chemotherapy. At approximately 16 months’ median follow-up, median overall survival was 21.1 months versus 12.7 months with durvalumab alone. One-year survival was nearly 80% versus 53%. Median progression-free survival was 7.4 versus 1.9 months, and objective response rates were 26.4% versus 4.1%.
Grade 3 or higher treatment-related adverse events occurred in 20.9% versus 10.8%. Separate updates showed median overall survival of 37.9 months in Phase 1b DeLLphi-303 and 13.6 versus 8.4 months with chemotherapy in Phase 3 DeLLphi-304. Amgen plans to share the results with regulatory authorities worldwide.
Amgen (AMGN) will host an investor webcast on October 24, 2026, in conjunction with the European Society of Medical Oncology Congress.
The call begins at 11:30 a.m. PT. Executives Murdo Gordon and Jean-Charles Soria, alongside other management team members, will discuss Amgen's oncology portfolio and selected data presented at ESMO 2026. The webcast will be publicly accessible and archived for replay for at least 30 days.
Amgen (AMGN) and AstraZeneca reported that TEZSPIRE met both co-primary endpoints in the Phase 3 CROSSING trial for eosinophilic esophagitis. Patients received 210 mg or 420 mg every four weeks. At week 24, tissue-based remission rates were 64.8% and 68.9%, respectively, versus 3.5% with placebo. Swallowing-difficulty scores fell 18.8 and 22.0 points from baseline versus 14.7 with placebo; both doses achieved statistical significance on both endpoints.
At week 52, tissue-based remission rates were 67.8% and 63.3% versus 5.4% with placebo. Swallowing-score reductions reached 22.1 and 24.0 points versus 13.2. Total endoscopic remission, meaning no visible disease features, occurred in 34.4% and 29.5% versus 4.1%. The most frequently reported adverse events were nasopharyngitis, headache and diarrhea. A threshold for clinically meaningful improvement in the endoscopic disease score has not been established.